Answers are grounded in this paper and cite their sources.
This viewpoint addresses FDA data on opioid risks in pain management, highlighting the need for studies and clear communication.
This Viewpoint discusses recent US Food and Drug Administration data on opioid-related risks and harms; highlights ways in which understanding of these risks and harms remains incomplete; and calls for required postmarketing opioid studies and improved regulatory communications to ensure safer, more effective pain care.
No takes yet. Share an insight, caveat, or question.
Bicket et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: